Skip to content

A pilot trial to examine the effectiveness and feasibility of the mobile application-based cognitive behavioral therapy for depression and anxiety

A pilot trial to examine the effectiveness and feasibility of the mobile application-based cognitive behavioral therapy for depression and anxiety - ICBT for depression and anxiety

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042193
Enrollment
11
Registered
2020-10-21
Start date
2021-02-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression and anxiety

Interventions

A mobile application-based cognitive behavioral therapy for 12 weeks

Sponsors

Chiba University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following conditions: 1) Have mild or moderately severe depressive symptoms (PHQ-9 score of 5 to 19 points) 2) Have mild or moderate anxiety symptoms (GAD-7 score of 5 to 14 points) 3) Men and women between the ages of 16 and 65 4) Those who receive medical treatment by a psychiatrist or psychosomatic physician. 5) Those who can visit Chiba University or have an interview with web conferencing software or telephone about once every four weeks 6) Those who can use the online program for about 12 weeks with PC, smartphone, or tablet 7) Those who understand the explanation in Japanese and have obtained the consent of the person (in the case of minors, the person and the guardian)

Exclusion criteria

Exclusion criteria: Those who meet any of the following conditions are not eligible: 1) Those who have an imminent risk of suicide 2) Persons with serious mental disorders such as organic brain disorders (including dementia), psychotic disorders, bipolar disorders, and drug dependence 3) Those who are not allowed to participate in this study by their principal doctor 4) Those who have difficulty in contacting researchers 5) Those who are receiving psychotropic drug therapy and whose prescription is expected to change during the period of participation in this study 6) Those who are currently receiving the therapy designated as prohibited 7) The principal investigator or the research coordinator judges that it is inappropriate to carry out this study safely.

Design outcomes

Primary

MeasureTime frame
change in sum of PHQ-9 and GAD-7 scores from pre- to post-12 week intervention

Countries

Japan

Contacts

Public ContactMasaki Tamura

Chiba University Graduate school of medicine

m.tamura.cmc@chiba-u.jp043-226-2027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026